NCR Online Journal

Comprehensive epidemiology insight of the Soft Tissue Sarcoma with Lung Metastasis & its treatment

 Breaking News
  • No posts were found

Comprehensive epidemiology insight of the Soft Tissue Sarcoma with Lung Metastasis & its treatment

March 16
19:57 2021
Comprehensive epidemiology insight of the Soft Tissue Sarcoma with Lung Metastasis & its treatment

 

DelveInsight has launched a new report on Soft Tissue Sarcoma with Lung Metastasis Epidemiology

 

About Soft Tissue Sarcoma with Lung Metastasis Disease

Soft tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas).

 

Download free sample copy- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-lung-metastases-epidemiology-forecast

 

Soft Tissue Sarcoma with Lung Metastasis Epidemiology

Once the systemic metastatic disease develops, the prognosis is typically poor. Patients with extremity sarcomas are more likely to develop the distant metastatic disease as the initial site of recurrence. In contrast, those with retroperitoneal and visceral sarcomas tend to present local recurrence. The lung is the most frequent site of metastasis from soft-tissue sarcomas. Due to the relative resistance of sarcoma to either chemotherapy or radiotherapy, compared to other solid tumors, surgical management of pulmonary metastases has been a pivotal therapy in this disease.

 

Important facts of Soft tissue sarcoma with Lung Metastasis epidemiology report

  • Sarcoma comprises a heterogeneous group of histologic subtypes with a propensity to metastasize to the lungs. Isolated pulmonary metastases occur in as many as 20% of patients diagnosed with soft tissue sarcoma and as many as 40% in those with primary bone sarcoma.
  • Soft tissue and bone sarcomas represent less than 1% of all malignancies diagnosed in the United States annually. The most common site of metastasis is the lung, with metastatic pulmonary disease occurring in 19–50% of patients.
  • Approximately 20–40% of patients with sarcoma develop pulmonary metastases. Unlike many epithelial cancers, sarcomas very often spread only to the lungs.

 

Soft tissue sarcoma with Lung Metastasis Epidemiology Segmentation

  • Total Incident Cases of STS in the 7MM [2017–2030]
  • Gender-specific Incidence of STS with lung metastasis in the 7MM [2017–2030]
  • Total Incident Cases of STS with lung metastasis in the 7MM [2017–2030]
  • Treatable Cases of STS with lung metastasis in the 7MM (2017–2030)

 

Soft tissue sarcoma with Lung Metastasis Prevalent Population

There were slightly more males (53.4%) patients with lung lesions only, as compared to females (46.6%). Approximately 20–40% of patients with sarcoma develop pulmonary metastases. Unlike many epithelial cancers, sarcomas very often spread only to the lungs.

 

Soft tissue sarcoma with Lung Metastasis Epidemiology: Report Highlights

  • 11-Year Forecast of STS with lung metastases
  • 7MM Coverage
  • Total incident cases of Soft tissue sarcoma
  • Total incident cases of STS with lung metastases
  • Gender-specific incident cases of STS with lung metastases
  • Subtype-specific incident cases of STS with lung metastases

 

Download free sample copy- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-lung-metastases-epidemiology-forecast

 

Table of content

1 Key Insights

2 Executive Summary of STS with lung metastases

3 Disease Background and Overview: STS with lung metastases

4 Epidemiology and Patient Population

5 United States Epidemiology

6 EU5 Epidemiology

7 Japan Epidemiology

8 Appendix

9 DelveInsight Capabilities

10 Disclaimer

11 About DelveInsight

 

What are the important reasons to buy this report here?

  • Develop business strategies by understanding the trends shaping and driving the 7MM STS with lung metastases epidemiology forecast.
  • The STS with lung metastases epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The STS with lung metastases epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

 

Related Report

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles